Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study | Zendy

Małgorzata Roś-Mazurczyk | Zendy; Anna Wojakowska | Zendy; Łukasz Marczak | Zendy; Krzysztof Polański | Zendy; Monika Pietrowska | Zendy; Joanna Polańska | Zendy; Rafał Dziadziuszko | Zendy; Jacek Jassem | Zendy; Witold Rzyman | Zendy; Piotr Widłak | Zendy

Open Access

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study

Author(s) -

Małgorzata Roś-Mazurczyk,

Anna Wojakowska,

Łukasz Marczak,

Krzysztof Polański,

Monika Pietrowska,

Joanna Polańska,

Rafał Dziadziuszko,

Jacek Jassem,

Witold Rzyman,

Piotr Widłak

Publication year - 2017

Publication title -

acta biochimica polonica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.452

H-Index - 78

eISSN - 1734-154X

pISSN - 0001-527X

DOI - 10.18388/abp.2017_1517

Subject(s) - lung cancer , metabolome , cancer , metabolomics , medicine , cancer screening , lung cancer screening , oncology , cohort , lung , pathology , bioinformatics , metabolite , biology

Blood biomarkers may support early diagnosis of lung cancer by enabling pre-selection of candidates for computed tomography screening or discrimination between benign and malignant screening-detected nodules. We aimed to identify features of serum metabolome distinguishing individuals with early-detected lung cancer from healthy participants of the lung cancer screening program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research